REVIEW article
Front. Cell Dev. Biol.
Sec. Membrane Traffic and Organelle Dynamics
This article is part of the Research TopicPlant and Probiotic Nanovesicles: Innovations and ApplicationsView all 3 articles
Plant-Derived Extracellular Vesicles: An Alternative and Complementary Therapeutic Approach for Genitourinary Tumors
Provisionally accepted
- 1Dpartment of Urology, Jiujiang University Clinic College, Jiujiang, China
- 2Jiujiang University Medical College, Jiujiang, China
- 3Lanxi People's Hospital, Zhejiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Over the past four decades, the incidence of genitourinary tumors has risen significantly, becoming a major global health concern. This trend necessitates the exploration of more effective treatment strategies. Although considerable progress has been made in treatments such as endocrine, immune, and targeted therapies, these malignancies often remain uncontrolled, especially when metastatic. Recent advances in nanobiomedicine have revealed plant-derived extracellular vesicles as a novel and promising anti-cancer therapeutic option. These natural nanoparticles exhibit high biocompatibility, targeted delivery capability, and renewable properties, positioning them at the forefront of innovative cancer treatment strategies. Their inherent anti-cancer properties—such as inducing cell cycle arrest, promoting apoptosis, and inhibiting metastasis—may offer new alternatives for treating genitourinary cancers. This review summarizes current research on plant-based treatments for genitourinary tumors, focusing on the potential mechanisms and applications of plant-derived extracellular vesicles, thereby suggesting new nanoscale alternative and complementary therapeutic avenues.
Keywords: plant-derived extracellular vesicles, Genitourinary tumors, Tumor drug resistance, adjuvant anticancer drugs, engineered extracellular vesicles
Received: 30 Aug 2025; Accepted: 27 Oct 2025.
Copyright: © 2025 Huang, Zhang, Lou, Feng and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guoqiang Feng, 37250235@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.